Semaglutide Generics
-
{
- All
- News
-
Dr Reddy's Wins Nod to Sell Generic Ozempic, Check Cost Of Weight-Loss Drug
- Wednesday April 29, 2026
- India News | Edited by Prateek Shukla
The entry of Dr Reddy's generic is triggering a price battle among pharmaceutical companies worldwide.
-
www.ndtv.com
-
Ozempic Might Preserve Lean Body Mass Better Than Mounjaro: Study
- Friday April 17, 2026
- Health | Written by Sambhav Kumar
Both tirzepatide and semaglutide belong to a class of drugs that mimic hormones involved in appetite regulation. Semaglutide works by mimicking GLP-1, a hormone that helps control hunger and blood sugar levels.
-
www.ndtv.com
-
Natural Ozempic, No Side Effects: Stanford Scientists Discover Peptide That Can Rival The GLP-1 Drug
- Wednesday April 15, 2026
- Health | Written by Sambhav Kumar
One of the most fascinating aspects of this discovery is the role of artificial intelligence. Researchers developed a tool called "Peptide Predictor" to scan all human protein-coding genes.
-
www.ndtv.com
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
- Monday March 30, 2026
- Health | Written by Sambhav Kumar
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
www.ndtv.com
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
- Monday March 30, 2026
- Health | Asian News International
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
www.ndtv.com
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
- Wednesday March 25, 2026
- Health | Written by Varsha Vats
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
www.ndtv.com
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
- Tuesday March 24, 2026
- Health | Reported by Tanushka Dutta
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
www.ndtv.com
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
- Tuesday March 24, 2026
- Health | Indo-Asian News Service
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
www.ndtv.com
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
- Monday March 23, 2026
- Health | Written by Shreya Goswami
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
www.ndtv.com
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
- Saturday March 21, 2026
- Health | Reported by Tanushka Dutta
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
www.ndtv.com
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
- Saturday March 21, 2026
- Feature | Edited by Nikhil Pandey
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
www.ndtv.com
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
- Saturday March 21, 2026
- Health | Indo-Asian News Service
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
www.ndtv.com
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
- Sunday March 22, 2026
- Health | Written by Dr Kona Lakshmi Kumari
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
www.ndtv.com
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
- Friday March 20, 2026
- Health | Written by Dr Hari Kishan Boorugu
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
www.ndtv.com
-
Dr Reddy's Wins Nod to Sell Generic Ozempic, Check Cost Of Weight-Loss Drug
- Wednesday April 29, 2026
- India News | Edited by Prateek Shukla
The entry of Dr Reddy's generic is triggering a price battle among pharmaceutical companies worldwide.
-
www.ndtv.com
-
Ozempic Might Preserve Lean Body Mass Better Than Mounjaro: Study
- Friday April 17, 2026
- Health | Written by Sambhav Kumar
Both tirzepatide and semaglutide belong to a class of drugs that mimic hormones involved in appetite regulation. Semaglutide works by mimicking GLP-1, a hormone that helps control hunger and blood sugar levels.
-
www.ndtv.com
-
Natural Ozempic, No Side Effects: Stanford Scientists Discover Peptide That Can Rival The GLP-1 Drug
- Wednesday April 15, 2026
- Health | Written by Sambhav Kumar
One of the most fascinating aspects of this discovery is the role of artificial intelligence. Researchers developed a tool called "Peptide Predictor" to scan all human protein-coding genes.
-
www.ndtv.com
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
- Monday March 30, 2026
- Health | Written by Sambhav Kumar
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
www.ndtv.com
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
- Monday March 30, 2026
- Health | Asian News International
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
www.ndtv.com
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
- Wednesday March 25, 2026
- Health | Written by Varsha Vats
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
www.ndtv.com
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
- Tuesday March 24, 2026
- Health | Reported by Tanushka Dutta
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
www.ndtv.com
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
- Tuesday March 24, 2026
- Health | Indo-Asian News Service
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
www.ndtv.com
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
- Monday March 23, 2026
- Health | Written by Shreya Goswami
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
www.ndtv.com
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
- Saturday March 21, 2026
- Health | Reported by Tanushka Dutta
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
www.ndtv.com
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
- Saturday March 21, 2026
- Feature | Edited by Nikhil Pandey
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
www.ndtv.com
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
- Saturday March 21, 2026
- Health | Indo-Asian News Service
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
www.ndtv.com
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
- Sunday March 22, 2026
- Health | Written by Dr Kona Lakshmi Kumari
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
www.ndtv.com
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
- Friday March 20, 2026
- Health | Written by Dr Hari Kishan Boorugu
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
www.ndtv.com